drugset / Trial / NCT07321106

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

NCT07321106 ↗

Phase 1 Recruiting 80 enrolled Cartography Biosciences
NaSequentialOpen-labelTreatment

Summary

This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer

Timeline

Start
2026-01-15
Primary completion
2029-04
Completion
2029-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CBI-1214 Unknown — —

Indications